These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34021248)

  • 1. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
    Stoll A; Bruns H; Fuchs M; Völkl S; Nimmerjahn F; Kunz M; Peipp M; Mackensen A; Mougiakakos D
    Leukemia; 2021 Dec; 35(12):3482-3496. PubMed ID: 34021248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
    Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
    Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
    Chester C; Ambulkar S; Kohrt HE
    Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
    Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
    Kohrt HE; Houot R; Goldstein MJ; Weiskopf K; Alizadeh AA; Brody J; Müller A; Pachynski R; Czerwinski D; Coutre S; Chao MP; Chen L; Tedder TF; Levy R
    Blood; 2011 Feb; 117(8):2423-32. PubMed ID: 21193697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
    Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD137 enhances the efficacy of cetuximab.
    Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
    J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
    Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD137 differentially regulates innate and adaptive immunity against Mycobacterium tuberculosis.
    Fernández Do Porto DA; Jurado JO; Pasquinelli V; Alvarez IB; Aspera RH; Musella RM; García VE
    Immunol Cell Biol; 2012 Apr; 90(4):449-56. PubMed ID: 21747409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
    Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
    J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.
    Lin W; Voskens CJ; Zhang X; Schindler DG; Wood A; Burch E; Wei Y; Chen L; Tian G; Tamada K; Wang LX; Schulze DH; Mann D; Strome SE
    Blood; 2008 Aug; 112(3):699-707. PubMed ID: 18519814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
    Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
    Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages.
    Jiang D; Chen Y; Schwarz H
    J Immunol; 2008 Sep; 181(6):3923-32. PubMed ID: 18768847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma.
    Saltarella I; Link A; Lamanuzzi A; Reichen C; Robinson J; Altamura C; Melaccio A; Solimando AG; Ria R; Mariggiò MA; Vacca A; Frassanito MA; Desaphy JF
    Biomed Pharmacother; 2024 Jul; 176():116877. PubMed ID: 38850654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD137, an attractive candidate for the immunotherapy of lung cancer.
    Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
    Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
    Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.